Myriad Genetics unveils resesrch at SMFM on cfDNA

Myriad Genetics (MYGN) announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine, SMFM, conference. The company’s “Fetal fraction amplification enables accurate prenatal cell-free DNA, cfDNA, screening at eight weeks gestation” study was awarded SMFM’s “Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics.” The study found that Prequel Prenatal Screen with AMPLIFY technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA screening is offered beginning at nine to 10 weeks’ gestation. At earlier gestational ages, the proportion of placental cfDNA, referred to as the fetal fraction, is often too low to allow for confident analysis. Prequel with AMPLIFY can overcome this limitation by increasing the FF. This study found that by using Prequel with AMPLIFY, the average FF was 12.5%, with a no-call rate of less than 0.5% between eight and 10 weeks of gestation.